Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study)
Santiago González-Santiago, Cristina Saura, Eva Ciruelos, José Luis Alonso-Romero, Pilar de la Morena, Marta Santisteban, María Isabel Gallegos Sancho, Alicia de Luna, E. Dalmau, Sònia Servitja, Manuel Ruíz Borrego, José Ignacio Chacón
Topics & Concepts
PertuzumabTrastuzumabTaxaneMedicineBreast cancerInternal medicineOncologyChemotherapyNeoadjuvant therapyClinical endpointCancerClinical trialHER2/EGFR in Cancer ResearchBreast Cancer Treatment StudiesBreast Lesions and Carcinomas